Latest Conference Coverage

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

Data from the CLARITY extension trial suggest that the durability of treatment with cladribine extended beyond 24 months in those with relapsing-remitting multiple sclerosis.

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

Compared with patients who initially received interferon treatment, those given ocrelizumab had superior disability progression after a 6-year follow-up.

Patients with a disease duration of <16 years demonstrated a significantly greater reduction in risk for confirmed disability progression (CDP) at 3 and 6 months.

Phase 2 STOP-AUST data suggest that the antifibrinolytic agent may be able to reduce ICH in spot sign positive patients with stroke when administered within 2 to 3 hours of onset, warranting further study.

New study data from ISC 2020 suggest that patients with stroke can be effectively treated with tenecteplase at a lower dose of 0.25 mg/kg, reducing the need for mechanical clot removal.

Stroke patients experienced higher rates of thrombolysis as well as faster alarm to treatment times when mobile stroke units were present.

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.

The model may help clinicians enact preventative measures for those with migraine with aura at an early stage.

The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine discussed the difficult treatment decisions faced when undergoing epilepsy surgery.

The director of the Pediatric Epilepsy Program and an MD candidate at Weill Cornell Medicine detail the steps needed to take to improve outcomes in status epilepticus.

Page B. Pennell, MD, president of the American Epilepsy Society, shared her thoughts on the epilepsy treatment landscape, managing women with epilepsy, and the need for multidisciplinary involvement and communication.

The president of the American Epilepsy Society and director of epilepsy research at Brigham and Women’s Hospital outlined the state of epilepsy care and what we can expect in 2020.

The director of the Pediatric Epilepsy Program is joined by an MD candidate from Weill Cornell Medicine to discuss the protocol used to treat patients with status epilepticus.

The epilepsy fellow at the hospital of the University of Pennsylvania detailed why locating the seizure onset zone plays a crucial role in successful epilepsy surgery.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine detailed the ongoing questions about assessing the gaps in breastfeeding between women with, and without, epilepsy.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the findings of the MONEAD study and their implications for women with epilepsy.

The medical director of the Comprehensive Epilepsy Clinic at Nicklaus Children’s Hospital shared his insight into the potential of using an SCN1A-targeted adeno-associated viral vector-based gene therapy in epilepsy.

The associate professor of neurology and director of the Women With Epilepsy Program at Northwestern University Feinberg School of Medicine spoke about the need for consistency in the messaging conveyed to women with epilepsy who are having children.

The professor of neurology and epilepsy specialist at the Cleveland Clinic Lerner College of Medicine explains the decision-making process surrounding epilepsy surgery.

Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, detailed the process and decisions that patients with epilepsy face when considering surgery.

The assistant professor of neurology at the University of Wisconsin detailed the importance of transition clinics for pediatric patients with epilepsy.

Lara Jehi, MD, professor of neurology and an epilepsy specialist at the Cleveland Clinic Lerner College of Medicine, spoke to her work on individualized risk assessments for epilepsy surgery candidates and the impact it can have for both physicians and patients alike.